Introduction: Women with multiple sclerosis (MS) are treated early in the disease course with
disease modifying therapies (DMT). Updated information is needed on pregnancy outcomes …

The active management of multiple sclerosis (MS) has been made possible during the last
two decades with the advent of disease-modifying therapies (DMTs), leading to improved …

Although pregnancy in women with multiple sclerosis (MS) is not generally considered high
risk, there are some associated therapeutic challenges. The pregnancy‐associated …

Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, and degenerative
disease that is up to three times more frequent in young women. MS does not alter fertility …

Purpose of this Review: This article is a systematic review on the influence pregnancy has
on multiple sclerosis and the resulting impact of disease-modifying therapies. Findings …

Multiple sclerosis (MS) is a major neurologic disorder which preferentially affects young
women of childbearing age. In the last two decades, a number of disease-modifying …

Purpose The purpose of this study is to describe dispensing patterns and comparative safety
of disease‐modifying therapies (DMTs) during pregnancy in women with multiple sclerosis …

BACKGROUND AND OBJECTIVE: Women with multiple sclerosis (MS) who intend to get
pregnant are often advised to discontinue disease modifying therapy (DMT) prior to …

Pregnancy is safe in most MS patients and does not negatively influence MS disease course
overall. Use of disease-modifying treatments around conception should be considered on a …

Multiple sclerosis is often diagnosed in patients who are planning on having children.
Although multiple sclerosis does not negatively influence most pregnancy outcomes, less is …